Precipio, Inc. reported financial results for the second quarter ended June 30, 2026, announcing a quarterly record revenue of $7.0 million, up 22% year-over-year from $5.7 million in Q2 2025 and increasing from $6.7 million in Q1 2026. The company returned to positive Adjusted EBITDA of $0.4 million compared to a loss of $(0.2) million in the prior quarter, driven by higher revenues and decreased stock-based compensation expense. Cash flow from operations was $0.7 million, resulting in an end-of-quarter cash balance exceeding $3 million, up from $1.1 million in Q2 2025. CEO Ilan Danieli highlighted that this cash position was achieved without a financing event, citing customer growth and momentum across pathology and product revenue streams. Precipio operates as a healthcare biotechnology company focused on developing diagnostic products and services to improve cancer diagnosis accuracy.